Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.

about

Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.

P2860

Q48287588-EE4DB8B3-2DC9-40EF-B7EB-CDFA8F9FB783

P2860

Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.

Item

http://www.wikidata.org/entity/Q38904887

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Biosimilar erythropoiesis-stim ...... ntibodies-a systematic review.

@en

type

Item

label

Biosimilar erythropoiesis-stim ...... ntibodies-a systematic review.

@en

prefLabel

Biosimilar erythropoiesis-stim ...... ntibodies-a systematic review.

@en

P1476

Biosimilar erythropoiesis-stim ...... antibodies-a systematic review

@en

P2093

Linda Fryklund

http://www.w3.org/2001/XMLSchema#string

Marianne Heibert Arnlind

http://www.w3.org/2001/XMLSchema#string

Sigurd Vitols

http://www.w3.org/2001/XMLSchema#string

P2860

Physiology and pharmacology of erythropoietin

Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

Is the decision on the use of biosimilar growth hormone based on high quality scientific evidence? - a systematic review.

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

The blue cross blue shield assessment technology review: summary of findings.

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.

P2888

s00228-016-2096-z

P304

1161-1169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-016-2096-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Göran Bertilsson

P577

2016-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024743984

http://www.w3.org/2001/XMLSchema#string

P698

27444173

http://www.w3.org/2001/XMLSchema#string

Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.

about

P2860

P2860

Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698